Companies in the News


SEATTLE — Sana Biotechnology, Inc. (Sana), focused on engineering cells as medicines for patients, announced today the funding of all tranches of its initial financing, raising over $700 million. 

With this financing, Sana’s shareholders include ARCH Venture Partners, Flagship Pioneering, Canada Pension Pl...


Founders: David Perry, Geoffrey von Maltzahn and Noubar Afeyan
CEO: David Perry
Launched: 2014
Headquarters: Boston
Funding: $850 million
Valuation: $3.5 billion
Key technologies: Artificial intelligence, machine learning
Industry: Agriculture, farming
Previous appearances on Disruptor 50 List: 2 (No. 1...


Cambridge-based Magenta Therapeutics announced today that it has entered a non-exclusive research and clinical collaboration agreement with Beam Therapeutics. The goal is to evaluate the potential use of MGTA-117, Magenta’s novel targeted antibody drug conjugate (ADC) for the conditioning of patients with...

Please reload